New England Biolabs Inc v F Hoffman-La Roche AG

New England Biolabs Inc, an American biotechnology company, initiated proceedings against F Hoffman-La Roche AG, a Swiss pharmaceutical corporation, over alleged patent infringement. The Federal Court of Australia was tasked with determining the validity of the patents held by the respondent and whether they had been infringed by the appellant. The crux of the dispute revolved around the interpretation and scope of the patents in question, specifically those related to a method of producing recombinant proteins. The court was required to decide whether the respondent's patents were valid and, if so, whether the appellant had infringed them by carrying out similar activities in Australia.

The court examined the language of the patents and the technical specifications, aiming to ascertain the precise scope of the protection they afforded. It was essential to interpret the claims in the context of the prior art and the common general knowledge at the relevant time. The respondent argued that the appellant's activities fell within the scope of the patents, while the appellant contended that the patents were invalid or that their activities did not constitute infringement. The court held that the patents were valid and that the appellant had indeed infringed them. The respondent's patents were found to be clear and not ambiguous, and the appellant's activities were found to be within the scope of the claims. The court also rejected the appellant's arguments regarding the validity of the patents.

Consequently, the appeal was dismissed, and the appellant was ordered to pay the respondent's costs, including the costs of the application for leave to appeal. The parties were also required to file any submissions regarding the costs of the Commissioner of Patents within seven days. The court's decision reinforced the importance of patent protection in the biotechnology industry and underscored the need for careful consideration of patent claims and their interpretation in the context of alleged infringement.